The Journal of Urology · 2017 · 24 citations · 21 references
MedicinePharmacologyPharmacotherapyPain ManagementPain MedicineVoiding DysfunctionBladder DysfunctionBladder Function AssessmentContinence AssessmentOveractive BladderOveractive Bladder ManagementUrinary IncontinenceBladder Overactivity TreatmentInadequate TreatmentLong-term Side EffectsMinimally Important DifferenceOnabotulinumtoxina TherapyOveractive Bladder SymptomsPharmacologic Bladder ManagementPhase Iii Clinical Trials
PURPOSE: We present the long-term effects of repeat onabotulinumtoxinA 100 U treatment on health related quality of life in patients with overactive bladder and urinary incontinence who had an inadequate response to and/or were intolerant of an anticholinergic. MATERIALS AND METHODS: Patients who completed either of 2, 24-week phase III trials could enter a 3-year extension study and request multiple onabotulinumtoxinA 100 U treatments as needed. Results of the I-QOL (Incontinence-Quality of Life) and KHQ (King's Health Questionnaire) are reported for up to 6 treatments. Consistency of the response to repeat onabotulinumtoxinA treatments was evaluated by classifying patients by the I-QOL response to the first treatment and analyzing responses to treatments 2 to 6. RESULTS: After onabotulinumtoxinA treatments 1 to 6, improvements in I-QOL scores were consistently 2 to 3 times the minimally important difference, and improvements in KHQ role limitations and social limitations domain scores were 5 to 6 and 3 to 4 times the minimally important difference, respectively. Most patients achieved or exceeded the minimally important difference for I-QOL and KHQ domain scores. Furthermore, 72.9% of patients who achieved or exceeded the minimally important difference for I-QOL after treatment 1 did so for all subsequent treatments. Of patients with a poor response after treatment 1, 38.3% achieved improvements greater than the minimally important difference for all subsequent treatments. CONCLUSIONS: In patients with overactive bladder and incontinence consistent and clinically meaningful improvements in health related quality of life were observed with repeat onabotulinumtoxinA 100 U treatments. A positive response after treatment 1 tended to predict similar responses to subsequent treatments, whereas a lack of response to treatment 1 did not preclude positive response(s) to later treatments.
21
Prevalence and burden of overactive bladder in the United States
Walter F. Stewart, J. Van Rooyen, Geoffrey W. Cundiff et al. · World Journal of Urology · 2003 · 2.3K citations · Full text
Medicine, Internal Medicine, Urology +13
Paul Abrams, Karl‐Erik Andersson, Apostolos Apostolidis et al. · Neurourology and Urodynamics · 2018 · 1.1K citations · Full text
Karin S. Coyne, Christopher Sexton, Debra E. Irwin et al. · British Journal of Urology · 2008 · 827 citations · Full text
Medicine, Internal Medicine, Urology +17
Quality of life of persons with urinary incontinence: Development of a new measure
Todd H. Wagner, Donald L. Patrick, Tamara Bavendam et al. · Urology · 1996 · 517 citations
Medicine, Urology, Female Urology +11